Company Filing History:
Years Active: 1998
Title: **Arie Goldlust: Innovator in Recombinant Technology**
Introduction
Arie Goldlust is a notable inventor based in Nez-Ziona, Israel, known for her contributions to the field of biotechnology. With a focus on recombinant polypeptides, she has made significant strides in medical innovations, particularly in the development of inhibitors that have important therapeutic applications.
Latest Patents
Arie Goldlust holds a patent for the "Production of recombinant factor Xa inhibitor of leech Hirudo." This groundbreaking invention offers a recombinant polypeptide characterized by the amino acid sequence X-tyr.sup.26 -gly.sup.110, where tyr.sup.26 -gly.sup.110 is identical to the specified sequence. The patent details a method for producing this polypeptide, which includes transforming a host cell with an expression plasmid, culturing the transformed cells for production, and methods of recovering the polypeptide.
Career Highlights
Arie is associated with Biotechnological General Corporation, where she applies her expertise to advance biotechnological solutions. With her innovative approach, she continues to drive the development of new therapeutic agents that have the potential to impact patient care positively.
Collaborations
In her career, Arie has worked alongside notable colleagues such as Moshe M. Werber and Elisha P. Zeelon. These collaborations have fostered an environment of innovation and have contributed to the progression of their groundbreaking projects in biotechnology.
Conclusion
Arie Goldlust's work as an inventor exemplifies the vital role of innovations in the medical field. Her patent on recombinant factor Xa inhibitors represents a significant advancement in biotechnology, highlighting her impact on science and medicine. As she continues to innovate, the potential benefits of her research are poised to enhance therapeutic options for a variety of medical conditions.